{"url_path":"/sec/inbx/8-k/2026-07-16/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000037-index.html","accession_number":"0002007919-26-000037","cik":"0002007919","ticker":"INBX","issuer_name":"Inhibrx Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000037-index.html","primary_entity_key":"0002007919","primary_entity_name":"Inhibrx Biosciences, Inc."},"word_count":91,"has_tables":true,"body_markdown":"Item 9.01.    Financial Statements and Exhibits.\n\n(d) Exhibits.\n\nExhibit No.Description\n\n10.1\n[Second Amendment to Loan and Security Agreement, dated July 15, 2026, among the Company, Oxford Finance LLC, and the other lenders party thereto](oxfordinhibrx-secondamendm.htm)\n\n99.1\n[Press Release issued by the Company on July 16, 2026](exhibit991-pressreleaseoxf.htm)\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: July 16, 2026\n\nINHIBRX BIOSCIENCES, INC.\n\nBy:/s/ Kelly Deck\n\nName:Kelly Deck\n\nTitle:Chief Financial Officer"}